Drug Profile
Sufentanil/triazolam sublingual - Talphera
Alternative Names: ARX-03; ARX-F03; sublingual sufentanil/triazolam NanoTab™; triazolam/sufentanilLatest Information Update: 11 Jan 2024
Price :
$50
*
At a glance
- Originator AcelRx Pharmaceuticals
- Developer Talphera
- Class Benzodiazepines; General anaesthetics; Hypnosedatives; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action GABA A receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pain; Sedation
Highest Development Phases
- No development reported Procedural pain; Sedation
Most Recent Events
- 09 Jan 2024 AcelRx Pharmaceuticals is now called Talphera
- 02 Nov 2020 No development reported - Phase-II for Procedural pain in USA (Sublingual) in November 2020 (AcelRx Pharmaceuticals pipeline)
- 02 Nov 2020 No development reported - Phase-II for Sedation in USA (Sublingual) in November 2020 (AcelRx Pharmaceuticals pipeline)